We advise using verapamil as an additional treatment for CPVT patients who continue to experience ventricular arrhythmias despite taking beta-blockers and/or flecainide [17]. Since beta-blockers and ICDs are efficient treatments for CPVT and SCD risk is present in 50% of cases, early diagnosis and subsequent preventive measures are made possible by genetic screening for the RYR2 mutation [18]. This evidence concerns the gene RYR2 and catecholaminergic polymorphic ventricular tachycardia.